CEVR analyzes the benefits, risks, and costs of strategies to improve health and health care.

About Us
Data

News & Events

Recent Publications

When are breakthrough therapies cost-effective?

Journal of Managed Care & Specialty Pharmacy

Olchanski N, Lin P, Yeh W, Kowal S, Cohen J. When are breakthrough therapies cost-effective? Journal of Managed Care & Specialty Pharmacy 2022

Racial and ethnic differences in hospice use and hospitalizations at end-of-life among Medicare beneficiaries with dementia

JAMA Network Open

Lin P, Zhu Y, Olchanski N, et al. Racial and Ethnic Differences in Hospice Use and Hospitalizations at End-of-Life Among Medicare Beneficiaries With Dementia. JAMA Netw Open. 2022;5(6):e2216260. doi:10.1001/jamanetworkopen.2022.16260

Trends in author-reported cost-effectiveness thresholds in the United States from 1995 to 2018: Implications for discount rates

Medical Decision Making

Pandya A, Paulden M, Zhu J, Lavelle TA, Hammitt J. Trends in Author-Reported Cost-Effectiveness Thresholds in the United States from 1995 to 2018: Implications for Discount Rates. Med Decis Making. 2022 May 7:272989X221097106. doi: 10.1177/0272989X221097106. Epub ahead of print. PMID: 35531945.

Patients’ access to 2018 FDA-approved drugs 1 year post approval

The American Journal of Managed Care

Panzer A, Margaretos N, Bridger N, Osani M, Lai R, Chambers J. Patients’ access to 2018 FDA-approved drugs 1 year post approval. The American Journal of Managed Care, April 2022, Volume 28, Issue 4

Addressing challenges to alternative payment models for new Alzheimer’s disease therapies for US commercial payers

PharmacoEconomics

Hlávka, J.P., Lavelle, T.A., Neumann, P.J. et al. Addressing Challenges to Alternative Payment Models for New Alzheimer’s Disease Therapies for US Commercial Payers. PharmacoEconomics (2022). https://doi.org/10.1007/s40273-022-01150-w

Cost-effectiveness of exome and genome sequencing for children with rare and undiagnosed conditions

Genetics in Medicine

Lavelle TA, Feng X, Keisler M, Cohen JT, Neumann PJ, Prichard D, Schroeder BE, Salyakina D, Espinal PS, Weidner SB, Maron JL, Cost-effectiveness of exome and genome sequencing for children with rare and undiagnosed conditions, Genetics in Medicine, 2022, , ISSN 1098-3600, https://doi.org/10.1016/j.gim.2022.03.005.

A systematic review of economic evaluations of COVID-19 interventions: Considerations of non-health impacts and distributional issues

Value in Health

Podolsky M, Present I, Neumann PJ, Kim DD, A Systematic Review of Economic Evaluations of COVID-19 Interventions: Considerations of Non-health Impacts and Distributional Issues, Value in Health, 2022, , ISSN 1098-3015, https://doi.org/10.1016/j.jval.2022.02.003.

The impact of broader value elements on cost-effectiveness analysis: Two case studies

Value in health

Ma S, Olchanski N, Cohen JT, Ollendorf DA, Neumann PJ, Kim DD, The Impact of Broader Value Elements on Cost-Effectiveness Analysis: Two Case Studies, Value in Health, 2022, , ISSN 1098-3015, https://doi.org/10.1016/j.jval.2022.01.025.

The history and future of the “ISPOR value flower”: Addressing limitations of conventional cost-effectiveness analysis

Value in Health

Neumann PJ, Garrison LP, Willke RJ. The History and Future of the “ISPOR Value Flower”: Addressing Limitations of Conventional Cost-Effectiveness Analysis. Value in Health. 2022 March 9. DOI:https://doi.org/10.1016/j.jval.2022.01.010

Patients' access to rare neuromuscular disease therapies varies across US private insurers

Orphanet Journal of Rare Diseases

Margaretos NM, Bawa K, Engmann NJ, Chambers JD. Patients' access to rare neuromuscular disease therapies varies across US private insurers. Orphanet J Rare Dis. 2022 Feb 5;17(1):36. doi: 10.1186/s13023-022-02182-3.

The certainty of uncertainty in health technology assessment

Health Affairs Forefront

The Certainty Of Uncertainty In Health Technology Assessment, Health Affairs Forefront, January 26, 2022. DOI: 10.1377/forefront.20220125.37540

Medicare’s Aducanumab decision highlights needed reforms to FDA and CMS regulatory pathways

Health Affairs Forefront

Medicare’s Aducanumab Decision Highlights Needed Reforms To FDA And CMS Regulatory Pathways, Health Affairs Forefront, January 25, 2022. DOI: 10.1377/forefront.20220121.566837

Herd immunity effects in cost‑effectiveness analyses among low‑ and middle‑income countries

Applied Health Economics and Health Policy

Ma, S., Lavelle, T.A., Ollendorf, D.A. et al. Herd Immunity Effects in Cost-Effectiveness Analyses among Low- and Middle-Income Countries. Appl Health Econ Health Policy (2022). https://doi.org/10.1007/s40258-021-00711-y

Developmental behavioral pediatrician perspectives on decision-making in early treatment planning for children with autism spectrum disorder

Journal of Developmental and Behavioral Pediatrics

Mulé C, Sliwinski, SK, Israel R, Lavelle TA, Developmental Behavioral Pediatrician Perspectives on Decision-Making in Early Treatment Planning for Children with Autism Spectrum Disorder, Journal of Developmental & Behavioral Pediatrics: October 12, 2021 - Volume - Issue - doi: 10.1097/DBP.0000000000001002

The CEVR Team

Our team of experienced, dedicated researchers is led by health economists Peter Neumann and Josh Cohen. Together we produce cutting-edge health care cost-effectiveness research.

Meet the CEVR Team

Our Databases

Our comprehensive databases provide the information individuals and organizations need to analyze the benefits, risks, and costs of strategies to improve health and health care.